HORSHOLM, Denmark, Dec. 10, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.
"Bill has been instrumental in bringing the company successfully through its development phase with regulatory approval of Envarsus® in both Europe and the US and we thank him for his dedicated contribution," said Mette Kirstine Agger, Chairman of the Board of Veloxis.
Envarsus® XR is indicated for the prophylaxis of organ rejection in kidney transplant patients and has been launched in a number of European countries. Earlier this week, Veloxis announced the launch of Envarsus XR in the US and is transitioning from a development company into a commercial company.
Dr. Polvino will be followed by Craig A. Collard who will take over the position as President and CEO with immediate effect.
Craig A. Collard has more than 20 years' track record of strategic and tactical leadership within the pharmaceutical industry. In 2003, he founded Cornerstone Therapeutics, Inc. and chaired the company until 2014 where it was sold to Chiesi Farmaceutici SpA for over USD 250M.
"We are very pleased that Craig A. Collard has accepted the offer as the new CEO of Veloxis. Craig brings substantial commercial experience to the company. We believe that with Craig the company will be well positioned to enter the phase of commercialization," said Mette Kirstine Agger.
For more information, please contact:
Veloxis Pharmaceuticals A/S Mette Kirstine Agger, Chairman of the Board Tel: +45 39 12 80 80
About Veloxis Pharmaceuticals Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ Copenhagen under the trading symbol NASDAQ: VELO.
For further information, please visit www.veloxis.com.
SOURCE Veloxis Pharmaceuticals A/S